PEG-ADA - AN ALTERNATIVE TO HAPLOIDENTICAL BONE-MARROW TRANSPLANTATION AND AN ADJUNCT TO GENE-THERAPY FOR ADENOSINE-DEAMINASE DEFICIENCY

被引:44
作者
HERSHFIELD, MS [1 ]
机构
[1] DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710
关键词
IMMUNODEFICIENCY; ENZYME REPLACEMENT THERAPY; POLYETHYLENE GLYCOL; ORPHAN DRUG;
D O I
10.1002/humu.1380050202
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
PEG-ADA is a long-circulating form of adenosine deaminase (ADA) that has been in use for >8 years as replacement therapy for severe combined immunodeficiency disease due to ADA deficiency. Treat ment with PEG ADA almost completely corrects metabolic abnormalities, allowing the recovery of a variable degree of immune function, Although not normal, the level of function achieved has in most eases been sufficient to protect against opportunistic and life threatening infections. PEG-ADA has been used as an alternative for patients who lack an HLA identical bone marrow donor, but are judged to be at too high a risk for undergoing HLA haploidentical marrow transplantation. To date, mortality and morbidity with PEG ADA have been less than for the latter procedure. PEG ADA has also been an important adjunct to attempts to develop somatic cell gene therapy for ADA deficiency, although its continued use poses a problem for evaluation of the benefit of gene therapy. As a true ''orphan drug'' developed to treat a very small patient population, the cost per patient of PEG ADA is very high. (C) 1995 Wiley-Liss, Inc.
引用
收藏
页码:107 / 112
页数:6
相关论文
共 22 条
  • [1] ARREDONDOVEGA FX, 1994, AM J HUM GENET, V54, P820
  • [2] DEVELOPMENT OF GENE-THERAPY FOR IMMUNODEFICIENCY - ADENOSINE-DEAMINASE DEFICIENCY
    BLAESE, RM
    [J]. PEDIATRIC RESEARCH, 1993, 33 (01) : S49 - S55
  • [3] COMPARISON OF RED-CELL TRANSFUSION AND POLYETHYLENE GLYCOL-MODIFIED ADENOSINE-DEAMINASE THERAPY IN AN ADENOSINE DEAMINASE-DEFICIENT CHILD - MEASUREMENT OF ERYTHROCYTE DEOXYADENOSINE TRIPHOSPHATE AS A USEFUL TOOL
    BORY, C
    BOULIEU, R
    SOUILLET, G
    CHANTIN, C
    ROLLAND, MO
    MATHIEU, M
    HERSHFIELD, M
    [J]. PEDIATRIC RESEARCH, 1990, 28 (02) : 127 - 130
  • [4] IGG ANTIBODY-RESPONSE TO POLYETHYLENE GLYCOL-MODIFIED ADENOSINE-DEAMINASE IN PATIENTS WITH ADENOSINE-DEAMINASE DEFICIENCY
    CHAFFEE, S
    MARY, A
    STIEHM, ER
    GIRAULT, D
    FISCHER, A
    HERSHFIELD, MS
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1992, 89 (05) : 1643 - 1651
  • [5] CHUN JD, 1993, ANN ALLERGY, V70, P462
  • [6] DAVIS S, 1981, CLIN EXP IMMUNOL, V46, P649
  • [7] DROR Y, 1993, BLOOD, V81, P2021
  • [8] EUROPEAN EXPERIENCE OF BONE-MARROW TRANSPLANTATION FOR SEVERE COMBINED IMMUNODEFICIENCY
    FISCHER, A
    LANDAIS, P
    FRIEDRICH, W
    MORGAN, G
    GERRITSEN, B
    FASTH, A
    PORTA, F
    GRISCELLI, C
    GOLDMAN, SF
    LEVINSKY, R
    VOSSEN, J
    [J]. LANCET, 1990, 336 (8719) : 850 - 854
  • [9] GIRAULT D, 1992, ARCH FR PEDIATR, V49, P339
  • [10] HERSHFIELD MS, 1993, PEDIATR RES, V33, pS42